Clinics often bundle FaceTite and Morpheus8 — both InMode platforms — as interchangeable "FDA-approved non-surgical facelifts." They are not interchangeable, they are not PMA-approved, and neither is cleared as a facelift.
Four distinctions:
- Mechanism. FaceTite is a minimally invasive radiofrequency-assisted lipolysis (RFAL) cannula placed under the skin. Morpheus8 is fractional radiofrequency microneedling (RFMN) through percutaneous needle arrays.
- Clearance. FaceTite rides the InMode RF System 510(k) K151793 (decision 19 February 2016, product code GEI, 21 CFR 878.4400), indicated for dermatological and general surgical procedures for electrocoagulation and hemostasis — not "lift," "jowl elimination," or "facelift." Clinical performance in that summary is listed as not applicable (ex-vivo histology versus predicate ThermiGen Symphony RF K130689).
- Warning scope. FDA's 15 October 2025 safety communication on RF microneedling (burns, scarring, fat loss, disfigurement, nerve injury) names microneedle electrode arrays. FaceTite is a GEI RFAL cannula, so that alert does not by its terms cover FaceTite. Subsurface RF still burns; Swanson 2022 reviewed those series.
- Ceiling. Neither device repositions SMAS or excises redundant skin the way a surgical facelift does. Ultherapy remains the energy device whose clearance actually uses the word "lift."
The buyer dossier for InMode's 510(k) map is InMode aesthetic device footprint. This page is the patient FaceTite-versus-Morpheus8 decision.
How does FaceTite differ from Morpheus8?
FaceTite is a single-session, tumescent, cannula procedure that heats subcutaneous fat and the fibroseptal network from the inside. Morpheus8 is a multi-session office treatment that places fractional thermal zones in dermis (and, at deeper settings, subdermis) through needles.
| Parameter | FaceTite (RFAL) | Morpheus8 (RFMN) |
|---|---|---|
| Energy delivery | Internal electrode + external surface electrode; bipolar RF through tissue between them | Fractional RF at needle tips (12 / 24 / 40 / T tips in K200947) |
| FDA 510(k) | K151793 (19 February 2016) | K192695 (27 December 2019), K200947 (2 July 2020), K240017 (13 June 2024, Morpheus8 90 applicator) |
| Product code (FDA database) | GEI | GEI on K192695, K200947, and K240017 |
| Indication language | Electrocoagulation and hemostasis | Electrocoagulation and hemostasis (K192695 also limits energy >62 mJ/pin to Fitzpatrick I–IV) |
| Typical format | One cannula session, 1–2 puncture sites | Series of sessions weeks apart |
| Anesthesia | Tumescent local (± oral sedation) | Topical anesthetic (± blocks or nitrous) |
| Fat effect | Intentional RFAL lipolysis | Unintended lipoatrophy risk at deep settings — see Morpheus8 fat-loss risk |
| Labeled RF output (K151793) | Up to 20 W at 1 MHz; internal cut-off range 50–70°C in the substantial-equivalence table | Up to 65 W at 1 MHz (K192695 / K200947 summaries) |
If the problem is focal jowl or submental fat with mild laxity, RFAL is the more direct tool. If the problem is texture, pores, acne scars, or crepe, RFMN is the texture tool — with the 2025 class warning attached.
What did FDA actually clear?
"FDA-approved non-surgical facelift" is wrong twice. Both devices are Class II 510(k) clearances (substantial equivalence), not PMA approvals. K151793's indications-for-use sentence is electrocoagulation and hemostasis. There is no US clearance that FaceTite lifts the face.
BodyTite, the body RFAL sibling, is K171593 (decision 10 October 2017, also GEI) — not 18 October. Same indication family, different anatomy.
Energy physics, without a cartoon cannula
FaceTite (RFAL). An internal electrode is introduced through a small access puncture into fat. An external electrode rides the skin. Current flows between them. The 510(k) lists an internal cut-off band of 50–70°C versus the predicate's wider band. Published RFAL technique papers (reviewed in Swanson 2022) discuss heating fibroseptal collagen in the mid-to-high 60s °C while trying to keep epidermal temperature much lower; those operating targets are literature and manufacturer technique, not a labeled "facelift temperature." If the external sensor loses contact or the internal probe rides too close to dermis, full-thickness burns happen quickly.
Morpheus8 (RFMN). Insulated needles enter to a programmed depth; RF fires at the exposed tips. K200947 lists 12-, 24-, 40-pin and T tips and energy/depth bands including 2–7 mm for larger tips. Marketing "8 mm Body" depth is not the number to treat as a 510(k) limit; the summary's listed range tops out at 7 mm. Fractional dermal heating is a wound-healing stimulus, not SMAS plication.
Does the October 2025 RF microneedling warning apply to FaceTite?
By its terms, no. The communication is titled for radiofrequency microneedling and describes arrays of needle-like electrodes. FaceTite is not that device class.
That does not mean FaceTite is warning-free. Swanson (Aesthetic Surgery Journal Open Forum, 2022, PMC9415206) reviewed subsurface RF series, mostly InMode. Cook et al. 2021 (n = 745, BodyTite/FaceTite/AccuTite, mixed body sites, some general anesthesia) recorded swelling, nodules, contour irregularity, and 2 burns. Swanson notes paid-investigator and stock-option conflicts for authors on that series. No large randomized FaceTite-versus-Morpheus8 trial was found in bounded ClinicalTrials.gov queries on 22 August 2026.
The RFMN warning itself — burns, grid scars, fat loss, nerve injury — is unpacked on FDA RF microneedling safety communication.
What the appointment actually involves
Skip the compound-pharmacy recipe. Ask who is operating the device, what anesthesia they use, and how they manage a burn.
FaceTite. Mark jowls, submental fat, and the marginal mandibular nerve path. Infiltrate tumescent local anesthetic. Make one or two small access punctures (often submental or pre-auricular). Fan the internal probe while watching the external temperature readout. Compression garment afterward. Expect several days of swelling and bruising, not a lunch-hour flush.
Morpheus8. Numb, degrease, place the tip fully before firing (incomplete insertion arcs the epidermis and prints a grid). Depth and energy should drop on thin faces and on Fitzpatrick V–VI. K192695's >62 mJ/pin → Fitzpatrick I–IV only limit is a labeled constraint, not optional folklore. Redness and stamped marks typically fade in a few days; PIH risk is higher on darker phototypes if energy is aggressive.
This page does not publish steroid tapers, filler-rescue doses, or tumescent concentrations. Complication management belongs to the treating clinician; your job is to ask who covers burns, neuropraxia, and contour dents after hours.
AccuTite is not a blepharoplasty
AccuTite is the smaller RFAL handpiece for tight zones (periorbital, brows, nasolabial). NCT04103619 is a proof-of-concept lower-eyelid study of AccuTite with or without Morpheus8 (completed 13 December 2021). A small exploratory protocol is not FDA clearance to replace surgical blepharoplasty. AccuTite can reduce a pinch of fat; it cannot excise skin folds or resuspend a canthus. "Scarless blepharoplasty" is clinic copy running past the GEI indication.
Combination therapy (EmbraceRF) stacks heat
InMode markets EmbraceRF as FaceTite plus Morpheus8 in one session: deep RFAL, then superficial fractional needles.
That pairing is a studied pattern, not a free upgrade. NCT03945422 treated premature jowl/neck laxity after facialplasty with AccuTite/FaceTite and Morpheus8 (completed 18 January 2021, open-label). NCT04103619 also allowed Morpheus8 with AccuTite around the eyelid. NCT04721405 is different: an observational vest-monitoring study after BodyTite/FaceTite, not a combination-superiority trial.
Two thermal injuries in one envelope increase edema, delayed healing, and burn risk if the operator is stacking energy without respect for perfusion. Combination is not a scam and not a requirement.
Who still needs a facelift?
Energy devices contract soft tissue. They do not plagiarize a deep-plane operation.
Swanson cites Chia et al. 2015: RF-assisted liposuction of one arm produced 13% surface-area reduction versus 8% on the unassisted control arm at 1 year — not statistically significant. That is the opposite of a "15–25% guaranteed shrink" marketing line. Treat contraction percentages on clinic websites as unsourced unless they name the paper.
Skip both devices and go to surgery if:
- You can pinch a large redundant fold along jawline or neck (skin excess, not a thin fat pad).
- Platysmal bands need muscle work, not heat.
- The face is already hollow; melting remaining fat with RFAL or deep RFMN will age you.
Skin of color is not a footnote. RFMN grid marks and PIH are the usual Morpheus8 complaint on Fitzpatrick IV–VI when energy is high or the pins do not seat fully. The K192695 cap (energy above 62 mJ/pin limited to types I–IV) exists because epidermal melanin changes how that heat is tolerated, not because darker skin "doesn't respond." FaceTite avoids a needle grid, but a full-thickness RFAL burn still heals with a higher PIH and scar risk on darker phototypes. Ask whether the operator treats type V–VI faces regularly, what energy they will not use, and how they would treat a burn — including pigment, not only wound closure.
The severity ladder versus facelift is on jowls without surgery vs facelift. Session pricing for the needle device is on Morpheus8 cost; this comparison does not repeat that menu.
Cost and downtime, without a fake national average
Cash-pay FaceTite is usually priced as one cannula case. Morpheus8 is usually priced as a series. Published clinic menus vary by city and by whether fat grafting, liposuction, or EmbraceRF is bundled. This page will not invent a US mean. Ask for:
- Device name and 510(k) (K151793 vs a Morpheus8 applicator).
- Whether the quote is one session or three.
- Who holds the handpiece (physician vs supervised injector) and who covers a burn.
- Downtime you can actually take: several days of garment and bruising for FaceTite; a long weekend of grid marks for RFMN.
Longevity claims of "3–5 years" for FaceTite are clinic marketing. Fat cells that are destroyed do not return, but aging, collagen loss, and gravity continue. There is no labeled duration on K151793.
A reasonable recovery picture, without a protocol: FaceTite usually means a compression garment, visible bruising, and social downtime measured in several days. Morpheus8 usually means erythema and a stamped grid that makeup may cover after 48–72 hours, repeated across a series. Stacking them (EmbraceRF) lengthens both. If you cannot take that time, neither device is a "lunch-hour facelift," and Ultherapy or a later surgical date is the honest alternative.
Frequently asked questions
What is better, FaceTite or Morpheus8?
Neither. FaceTite for focal fat plus mild laxity. Morpheus8 for skin quality, with the RFMN warning and the Fitzpatrick energy cap in mind.
Is FaceTite better than Ultherapy?
Different physics. FaceTite is invasive RFAL under tumescent anesthesia. Ultherapy is non-invasive micro-focused ultrasound and is the energy device with a lift-worded clearance. Fat under the chin favors RFAL; no-puncture lifting favors Ultherapy — if you are a candidate at all.
What are the potential downsides of FaceTite?
Swelling, bruising, compression, temporary marginal-mandibular weakness, contour irregularity, and full-thickness burns. It is not a lunch-hour treatment.
Does FaceTite get rid of jowls permanently?
It can permanently reduce treated fat. It does not freeze the SMAS in youth. Residual skin excess still needs a facelift.
How long does Morpheus8 take to show results?
Texture changes over weeks; collagen remodeling is quoted in series as months after the last session. That timeline is clinical convention, not a 510(k) effectiveness trial.
Sources
- FDA 510(k) Database: K151793 — InMode RF System (Decision Date: February 19, 2016). Product Code: GEI. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K151793
- FDA 510(k) Summary PDF: InMode RF System K151793 (February 19, 2016). Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf15/K151793.pdf
- FDA Safety Communication: Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling (Issued October 15, 2025). Available at: https://www.fda.gov/medical-devices/safety-communications/potential-risks-certain-uses-radiofrequency-rf-microneedling-fda-safety-communication
- PubMed Central: Swanson E. A Systematic Review of Subsurface Radiofrequency Treatments. 2022. PMC9415206. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9415206/
- ClinicalTrials.gov: AccuTite/FaceTite and Morpheus8 after Facialplasty (NCT03945422). Available at: https://clinicaltrials.gov/study/NCT03945422
- ClinicalTrials.gov: AccuTite with or without Morpheus8 for Lower-Eyelid Rejuvenation (NCT04103619). Available at: https://clinicaltrials.gov/study/NCT04103619
- FDA 510(k) Database: K171593 — InMode RF System / BodyTite family (Decision Date: October 10, 2017). Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K171593
- FDA Aesthetic Cosmetic Devices: Microneedling Devices (Updated October 15, 2025). Available at: https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/microneedling-devices
- FDA 510(k) Summary: K192695 — InMode System with Morpheus8 (Fractora) Applicators (Decision Date: December 27, 2019), including the >62 mJ/pin Fitzpatrick I–IV limit. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf19/K192695.pdf
- FDA 510(k) Database: K200947 (July 2, 2020) and K240017 (June 13, 2024). Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K200947 and https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K240017
- ClinicalTrials.gov: Post-RFAL observational monitoring (NCT04721405). Available at: https://clinicaltrials.gov/study/NCT04721405
